Erdheim-Chester Disease
New Erdheim-Chester disease research, summarized each month in plain language.
2026 so far: So far in 2026 (January-September), targeted therapy matched to MAPK-pathway mutations was repeatedly linked to symptom and scan improvements, while organ complications (kidney failure/transplant and cardiac rhythm disease) strongly shaped real-world care. Read the 2026 review
We also cover clinical trials.
Yearly update
2026 so far
- Targeted therapy results. Benefits were reported more often, but toxicity still shaped care.
- ECD with blood disorders. A defined subgroup gained comparative response data this year.
- Kidney transplant experience. Transplant moved from theoretical to reported, with mixed outcomes.
- Heart rhythm problems. Case reports emphasized rhythm risk even when scans improved.
- Testing and imaging choices. More options appeared for biopsy, stains, and organ-specific imaging.
New
September 2026
- BRAF-targeted treatment. Small reports linked these drugs to better scans and symptoms.
- Muscle injury risk. One patient had severe muscle breakdown, leading to a lower dose.
- BRAF testing differences. A tissue stain looked negative, but DNA testing found BRAF V600E.
- Brain-only ECD case. One person improved after combined chemotherapy when earlier treatments failed.
August 2026
- Slow heart rhythms. Heart involvement was linked to slow or dangerous rhythms.
- Pacemakers and ICDs. Devices were used when the heart's electrical signals failed.
- Biopsy for diagnosis. Biopsy clarified unexpected findings in the breast or ureter.
- Bone biopsy injury. One report described a leg fracture after a bone biopsy.
July 2026
- Scan choice by organ. PET/MRI showed more brain detail; PET/CT showed lungs better.
- Copeptin blood test. Copeptin may help spot a water-balance hormone problem.
- Brain artery involvement. Some reports linked brain artery disease to worse outcomes.
June 2026
- Targeted therapy results. Trametinib-based treatment often improved symptoms and scan findings.
- Treatment side effects. Side effects were common and often led to dose changes.
- Lung biopsy approach. Lung cryobiopsy often confirmed ECD and sometimes supported mutation testing.
May 2026
- Cladribine outcomes over time. In routine-care reports, some people improved on cladribine, but some later relapsed after an earlier response.
- Cladribine blood count and infection risk. With cladribine, low lymphocyte counts were very common, and infections were reported in some patients.
- Vemurafenib in BRAF V600E ECD. Case reports described improvement or stable disease with vemurafenib in some people with BRAF V600E–mutated ECD.
- PET scans and genetic testing. PET imaging plus genetic testing helped identify ECD in cases that were difficult to recognize.
April 2026
- Targeted therapy response. In ECD with a myeloid neoplasm, kinase inhibitors were linked with higher ECD response rates than pegylated interferon-alpha.
- Blood disorder progression. Over about 6 months, myeloid neoplasm progression looked similar across the compared treatments.
- Brain symptoms vs scans. Some thinking, mood, sleep, or behavior symptoms continued even when brain imaging suggested remission.
- Diagnostic overlap (IgG4-like). IgG4-like features sometimes made it harder to distinguish ECD from other inflammatory diseases.
March 2026
- Gene-matched treatment. Some reports described improvement after using a targeted medicine that matched a specific gene change.
- Outcomes can still differ. Other reports showed that some severe cases had poor outcomes even after multiple treatment attempts.
- Confirming ECD. Reports described confirming ECD by combining PET-CT imaging, a biopsy, and gene testing.
February 2026
- Kidney transplant outcomes. In a small number of ECD-related kidney failure cases, kidney transplantation had very different outcomes, ranging from years of graft function to severe infections and signs of ECD returning near the transplanted kidney.
- Biopsy plus imaging for diagnosis. One report supported an ECD diagnosis using a biopsy together with classic imaging patterns, even when symptoms were limited.
- CD71 to separate look-alike diseases. CD71 staining was strongly positive in Rosai-Dorfman disease but usually negative in several similar conditions, which may help reduce mix-ups in difficult pathology cases.
- Treatment choices vary by patient. Case reports described very different treatment plans, including one person who improved on pegylated interferon-alpha when a targeted drug was not available.
January 2026
- Stains that support diagnosis. Cyclin D1 and pERK staining was often positive in ECD tissue and usually negative in look‑alike conditions, which can help when biopsy findings are difficult to interpret.
- Biopsy in difficult-to-reach areas. In two reported cases, an image‑guided skull‑base biopsy provided a definitive diagnosis without complications, showing one option when lesions are hard to access.
- Examples of treatment response. Single‑patient reports described symptom improvement with targeted therapy in BRAF V600E‑positive ECD (including bone pain and some neurologic symptoms), but these cases do not show what is typical.
- Multisystem and chest involvement. Registry and lung‑involvement reports again described ECD as often affecting multiple organs, with chest involvement frequently causing symptoms and care often involving several specialties.
Get the monthly update by email
Subscribe here to receive an email when a new monthly Erdheim-Chester disease update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).